Pyoderma gangrenosum
Pyoderma gangrenosum er en sjelden, inflammatorisk hudsykdom der smertefulle pustler eller knuter blir til sår som gradvis vokser. Pyoderma gangrenosum er ikke smittsomt. Behandlinger kan omfatte kortikosteroider, ciklosporin eller forskjellige monoklonale antistoffer. Selv om det kan påvirke mennesker i alle aldre, rammer det stort sett folk i 40- og 50-årene.
☆ I 2022 Stiftung Warentest-resultatene fra Tyskland var forbrukertilfredsheten med ModelDerm bare litt lavere enn med betalte telemedisinkonsultasjoner.
På benet til en person med ulcerøs kolitt.
References
Pyoderma gangrenosum er en sjelden hudtilstand som forårsaker smertefulle sår med røde eller lilla kanter. Det er klassifisert som en inflammatorisk sykdom og er en del av en gruppe som kalles nøytrofile dermatoser. Årsaken til pyoderma gangrenosum er kompleks, og involverer problemer med både medfødt og adaptiv immunitet hos mennesker som er genetisk utsatt. Nylig har forskere fokusert på hårsekken som et potensielt utgangspunkt for sykdommen.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum er en sjelden hudtilstand som forårsaker ekstremt smertefulle sår. Selv om vi ikke helt forstår årsaken, vet vi at det innebærer økt aktivitet av visse immunceller. Å behandle sykdommen er fortsatt ikke lett. Vi har ulike medikamenter som undertrykker immunsystemet eller modifiserer aktiviteten. Ved siden av disse fokuserer vi også på behandling av sårene og smertehåndtering. Kortikosteroider og ciklosporin er ofte førstevalget for behandling, men i det siste har det vært mer forskning på bruk av biologiske terapier som TNF-α-hemmere. Disse biologiske stoffene foretrekkes i økende grad, spesielt hos pasienter med andre inflammatoriske tilstander, og de brukes tidligere i sykdomsprosessen.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
